AUTO-CD

COELIAC DISEASE: UNDERSTANDING HOW A FOREIGN PROTEIN DRIVES AUTOANTIBODY FORMATION

 Coordinatore  

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Non specificata
 Totale costo 2˙291˙045 €
 EC contributo 2˙291˙045 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-05-01   -   2017-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITETET I OSLO

 Organization address address: Problemveien 5-7
city: OSLO
postcode: 313

contact info
Titolo: Mr.
Nome: Hans
Cognome: Mossin
Email: send email
Telefono: +47 22857659
Fax: +47 22844654

NO (OSLO) hostInstitution 2˙291˙045.00
2    UNIVERSITETET I OSLO

 Organization address address: Problemveien 5-7
city: OSLO
postcode: 313

contact info
Titolo: Prof.
Nome: Ludvig Magne
Cognome: Sollid
Email: send email
Telefono: +47 23073811
Fax: +47 23073510

NO (OSLO) hostInstitution 2˙291˙045.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

patients    anti    either    expressed    deamidation    iga    reactive    plasma    transamidation    vh    cd    autoantibodies    models    dq    cells    glutamine    antibodies    membrane    gluten    ig    antigen    exposure    subjects    tested    tg    disease    mabs    crosslinking   

 Obiettivo del progetto (Objective)

'The goal of this project is to understand the mechanism of how highly disease specific autoantibodies are generated in response to the exposure to a foreign antigen. IgA autoantibodies reactive with the enzyme transglutaminase 2 (TG2) are typical of coeliac disease (CD). These antibodies are only present in subjects who are HLA-DQ2 or -DQ8, and their production is dependent on dietary gluten exposure. This suggests that CD4 gluten reactive T cells, which are found in CD patients and which recognise gluten peptides deamidated by TG2 in context of DQ2 or DQ8, are implicated in the generation of these autoantibodies. Many small intestinal IgA plasma cells express membrane Ig hence allowing isolation of antigen specific cells. Whereas control subjects lack anti-TG2 IgA plasma cells, on average 10% of the plasma cells of CD patients are specific for TG2. We have sorted single TG2 reactive IgA plasma cells, cloned their VH and VL genes and expressed recombinant mAbs. So far we have expressed 26 TG2 specific mAbs. There is a strong bias for VH5-51 usage, and surprisingly the antibodies are modestly mutated. TG2 acts on specific glutamine residues and can either crosslink these to other proteins (transamidation) or hydrolyse the glutamine to a glutamate (deamidation). None of the 18 mAbs tested affected either transamidation or deamidation leading us to hypothesise that retained crosslinking ability of TG2 when bound to membrane Ig of B cells is an integral part of the anti-TG2 response. Four models of how activation of TG2 specific B cells is facilitated by TG2 crosslinking and the help of gluten reactive CD4 T cells are proposed. These four models will be extensively tested including doing in vivo assays with a newly generated transgenic anti-TG2 immunoglobulin knock-in mouse model.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

EUROEVOL (2010)

Cultural Evolution of Neolithic Europe

Read More  

SPEAR (2012)

"Specialisable, Programmable, Efficient and Robust Microprocessors"

Read More  

ROBINSCA (2012)

"New and more individualised population-based screening for cardiovascular disease; from a RCT including selfassessments, primary care and coronary artery calcification score to modelling risk-benefit"

Read More